Triple or Quadruple Combination DAAs Treatment for Subjects With HCV GT 1b Infection

Summary

This is a phase 2a, open-label, randomized study. The study is designed to test the hypothesis that the nucleoside inhibitor sofosbuvir combined with NS5A inhibitor daclatasvir and NS5B non-nucleoside inhibitor CDI-31244 with/without the protease inhibitor asunaprevir will result in high SVR rate with a shortened treatment duration (2 weeks) in non-cirrhotic HCV genotype 1b-infected subjects.

Timeline

Start

2019-05-01

Primary completion

2020-04-15

Completion

2020-04-30

Drugs

Indications